Is Archit Organosys overvalued or undervalued?

As of 17 October 2025, Archit Organosys has moved from a fair to an attractive valuation grade, indicating a positive shift in its perceived value. The company is currently considered undervalued, especially when compared to its peers in the commodity chemicals sector. Key ratios include a PE ratio of 154.30, an EV to EBITDA of 18.85, and a PEG ratio of 0.02, which suggests strong growth potential relative to its price.
In comparison to its peers, Archit Organosys stands out with its attractive valuation despite a high PE ratio, while Solar Industries and Gujarat Fluoroch are deemed very expensive with PE ratios of 100.67 and 65.14, respectively. The company's recent stock performance has lagged behind the Sensex, particularly over the past month and year, but it has shown significant gains over the last five years, outperforming the index. This combination of factors reinforces the conclusion that Archit Organosys is currently undervalued in the market.